Optimizing Control of Fever & Pain in Clinical Settings – An in-Vitro Investigation of the Dissolution and Disintegration Characteristics of Optizorb Technology in Acetaminophen Tablets versus Other Marketed Products
Main Article Content
Abstract
Reduced inter-patient variability and consistent therapeutic effects are prerequisites in formulating drugs for reliable fever and pain control. The bioavailability of paracetamol is variable, leading to variable onset and duration of action. Optizorb technology incorporates a patented technology aimed at rapid dissolution and absorption of active ingredients, and improving the bioavailability of paracetamol. This study compared the dissolution of various paracetamol formulations versus the patented 'Optizorb' technology-based paracetamol tablets (Crocin Advance 650), determined the rate of disintegration in aqueous media and resultant changes in pH, and analyzed the residue profile. The dissolution test utilized media closely resembling the gastrointestinal environment (0.1N HCl, pH 5.8 phosphate buffered medium and pH 6.8 phosphate buffered medium). The disintegration test was performed using 1,000 mL of water as disintegration media. In 0.1N HCL, Crocin 650 mg tablets released 61% of the drug at 1-minute time interval, and 94% at the 3-minute time interval. The disintegration time for Crocin 650 was 48 seconds in water. Crocin 650 exhibited complete disintegration and dissolution in water, leaving no residues in the medium. Crocin Advance 650 with Optizorb technology ensures rapid, consistent drug release and may provide clinically relevant reduction in inter- and intra-patient variability and improved bioavailability.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Johnson Q, Borsheski RR, Reeves-Viets JL. Pain management mini-series. Part I. A review of management of acute pain. Mol Med. 2013;110(1):74–79. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179627/.
II. Holgersson J, Ceric A, Sethi N, et al. Fever therapy in febrile adults: Systematic review with meta-analyses and trial sequential analyses. BMJ. 2022;378:e069620. Available from:
https://www.bmj.com/content/bmj/378/bmj-2021-069620.full.pdf.
III. Alorfi NM. Pharmacological methods of pain management: Narrative review of medication used. Int J Gen Med. 2023;16:3247–3256. Available from: https://www.dovepress.com/pharmacological-methods-of-pain-management-narrative-review-of-medicat-peer-reviewed-fulltext-article-IJGM.
IV. Ratain MJ, Plunkett WK Jr. Principles of Pharmacokinetics. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK12815/.
V. Wen H, Jung H, Li X. Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges. AAPS J. 2015;17(6):1327–1340. Available from:
https://link.springer.com/article/10.1208/s12248-015-9814-9.
VI. Abebe K, Beressa TB, Yimer BT. In-vitro evaluations of quality control parameters of paracetamol tablets marketed in Gondar City, Northwest Ethiopia. Drug Healthcare Patient Saf. 2020;12:273–279. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762764/.
VII. Arerusuoghene AC, Eziuzo OS, Afokoghene AJ et al. Solubility and dissolution optimization of paracetamol using in situ micronization by solvent change method. Int. J. Biosci. 2022;21(3): 8–19. Available from: https://www.innspub.net/wp-content/uploads/2022/09/IJB-V21-No3-p8-19.pdf.
VIII. Marchant B. Pharmacokinetic factors influencing variability in human drug response. Scand J Rheumatol Suppl. 1981;39:5–14. Available from: https://www.tandfonline.com/doi/pdf/10.3109/03009748109095328.
IX. Markl D, Zeitler JA. A review of disintegration mechanisms and measurement techniques. Pharm Res. 2017;34(5):890–917. Available from:
https://link.springer.com/article/10.1007/s11095-017-2129-z.
X. Prescott LF. Gastric emptying and drug absorption. Br J Clin Pharmac. 1974;1:189–190. Available from: https://bpspubs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1365-2125.1974.tb00234.x.
XI. Gupta A, Hunt RL, Shah RB, et al. Disintegration of highly soluble immediate release tablets: A surrogate for dissolution. AAPS PharmSciTech. 2009;10(2):495–499. Available from:
https://link.springer.com/article/10.1208/s12249-009-9227-0.
XII. Paul A. Drug Absorption and Bioavailability. In: Raj, G., Raveendran, R. (eds) Introduction to basics of pharmacology and toxicology. Springer, Singapore. 2019. Available from: https://doi.org/10.1007/978-981-32-9779-1_5.
XIII. Alagga AA, Gupta V. Drug absorption. [Updated 2023 Jun 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557405/.
XIV. Nimmo WS. Drugs, diseases and altered gastric emptying. Clin Pharmacokinet. 1976;1(3):189–203. Available from:
https://link.springer.com/article/10.2165/00003088-197601030-00002.
XV. Chaw CS, Yazaki E, Evans DF. The effect of pH change on the gastric emptying of liquids measured by electrical impedance tomography and pH-sensitive radiotelemetry capsule. Int J Pharmaceutics. 2001;227:167–175. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0378517301007955.
XVI. Rachid O, Rawas-Qalaji M, Simons FE, et al. Dissolution testing of sublingual tablets: A novel in vitro method. AAPS PharmSciTech. 2011;12(2):544–552. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3134647/.
XVII. Dissolution testing of immediate release solid oral dosage forms. FDA. August, 1997. Available from: https://www.fda.gov/media/70936/download#:~:text=The%20volume%20of%20the%20dissolution,pH%206.8%20should%20be%20employed.
XVIII. Opanasopit P, Aumklad P, Kowapradit J, Ngawhirunpat T, Apirakaramwong A, Rojanarata T, et al. Effect of salt forms and molecular weight of chitosans on in vitro permeability enhancement in intestinal epithelial cells (Caco-2). Pharm Dev Technol 2007; 12(5):447-455. Available from: https://www.tandfonline.com/doi/full/10.1080/10837450701555901.
XIX. Abdullahu B, Morina N, Islami H. Study of formulation of mild forms of paracetamol in medical practice. Mater Sociomed. 2012;24(3):148–150. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633388/.
XX. Crocin 650. Available from:
https://www.haleonhealthpartner.com/en-in/pain-relief/brands/crocin/products/crocin-65.
XXI. Wilson CG, Clarke CP, Starkey YYL, Clarke GD. Comparison of a novel fast-dissolving acetaminophen tablet formulation (FD-APAP) and standard acetaminophen tablets using gamma scintigraphy and pharmacokinetic studies. Drug Development and Industrial Pharmacy. 2011;37(7):747–753. Available from: https://www.tandfonline.com/doi/full/10.3109/03639045.2010.538058.
XXII. Raffa RB, Pergolizzi JV, Taylor R Jr, Deker JF, Patrick JT. Acetaminophen (paracetamol) oral absorption and clinical influences. Pain Pract. 2014;14(7):668–677. Available from:
https://onlinelibrary.wiley.com/doi/10.1111/papr.12130.
XXIII. Jambhekar SS, Breen PJ. Drug dissolution: Significance of physicochemical properties and physiological conditions. Drug Discov Today. 2013;18(23-24):1173–1184. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1359-6446(13)00280-8.
XXIV. McGill MR, Jaeschke H. Metabolism and disposition of acetaminophen: Recent advances in relation to hepatotoxicity and diagnosis. Pharm Res. 2013;30(9):2174–2187. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3709007/.
XXV. Robinson S. The importance of tablet disintegration and its mechanisms. J Pharma Reports. 2023;7:176. Available from: https://www.longdom.org/open-access/the-importance-of-tablet-disintegration-and-its-mechanisms-101422.html.